MOTS-c + SS-31 Blend

How this combination works

The community rationale pairs two different levels of mitochondrial support. MOTS-c signals through AMPK and PGC-1α to regulate energy metabolism and mitochondrial biogenesis. SS-31 binds cardiolipin in the inner mitochondrial membrane to stabilise cristae, reduce oxidative stress and support ATP production in existing mitochondria. The idea is to have more mitochondria, each working better. The combination is untested, and both compounds' evidence for energy or performance in healthy humans is limited. This rationale is mechanistic inference only.

Combined mechanism

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome. It inhibits the folate cycle and de novo purine synthesis, leading to AMPK activation. AMPK then regulates PGC-1α, mTORC1 and other effectors involved in mitochondrial biogenesis, glycolysis and oxidative-stress responses. SS-31 (elamipretide) is a tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilising cristae structure, scavenging ROS and enhancing ATP production. A CRISPR screen identified phospholipid scramblase 3 (PLSCR3) as an essential target mediating its effects. The two act at different points — nuclear/AMPK signalling vs inner-membrane structure. No human pharmacokinetic or pharmacodynamic data exist for the combination.

What each component does

Evidence base for this combination

No combo-specific RCTNo study testing MOTS-c and SS-31 together is cited in either compound's approved file (reviewed 2026-10-16). Any rationale for combining them is mechanistic inference from each compound studied on its own, not evidence that the combination works or is safe.

Safety considerations for this combination

• No combination-specific safety data exist for MOTS-c + SS-31. The signals below come from each compound studied on its own. Component approved files
• MOTS-c's approved file lists no compound-specific safety signals. That reflects limited study, not established safety; see the MOTS-c peptide page. MOTS-c approved file
• SS-31's approved file lists no compound-specific safety signals. That reflects limited study, not established safety; see the SS-31 peptide page. SS-31 approved file

Contraindications

• MOTS-c + SS-31 has not been evaluated as a combination in any clinical trial. The lack of combination-specific contraindications reflects that absence of study, not established safety. No combination study cited in either component file

Related blends